- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Federal 340b Drug Discount Program May be Reformed
New recommendations suggest reforming the federal 340b drug discount program. Originally designed to help providers serve the poor or underinsured, misuse has raised concerns for greater transparency in prices and how hospitals are using 340b savings.
New recommendations suggest reforming the federal 340b drug discount program. Originally designed to help providers serve the poor or underinsured, misuse has raised concerns for greater transparency in prices and how hospitals are using 340b savings. Modern Healthcare reports:
Safety net hospitals issued recommendations Tuesday for reforming the federal 340b drug discount program, which was designed to help clinics and hospitals serving the poor and uninsured but has become controversial because of alleged misuse by some hospitals.
The recommendations included increased transparency of 340b prices and how hospitals use 340b savings, audits of drug manufacturers and more scrutiny of contract pharmacies that participate in the program. They were released by the Safety Net Hospitals for Pharmaceutical Access, a trade group that represents more than half of the participating 340b hospitals.
Roughly one third of the nation's hospitals participate in the 340b program, and that growth has fueled a debate about reforming the decades-old program.
Read the full story here: http://bit.ly/16qozWX
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage
April 4th 2025This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.
Read More
